Cargando…
Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors
Chimeric antigen receptor (CAR)-T cells have enormous potentials for clinical therapies. The CAR-T therapy has been approved for treating hematological malignancies. However, their application is limited in solid tumors owing to antigen loss and mutation, physical barriers, and an immunosuppressive...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9315443/ https://www.ncbi.nlm.nih.gov/pubmed/35903099 http://dx.doi.org/10.3389/fimmu.2022.936496 |